Laurus Lab: Richcore acquisition marks entry into biotech

Laurus Lab: Richcore acquisition marks entry into biotech

Laurus Labs share rose 5% in early trade on Thursday after the pharma firm inked a definitive agreement to acquire 72.55% of Richcore’s stake from Eight Roads Ventures and VenturEast for Rs 246.67 crore.
Share of Laurus Labs gained 4.82% to Rs 298.80 against the previous close of Rs 285.05 on BSE.
The acquisition of Richcore marks Laurus Labs’ entry into the broader biologics and biotechnology segments, providing the company access to its high growth areas, globally and in India.
Through this acquisition, Laurus Lab has not only cut short the gestation period but will provide a quantum jump in revenue.

Richcore is a biotech company based in Bengaluru and develops products critical for biological drugs; it also helps global customers contract research and scale-up their bioprocesses by providing contract research, development, and manufacturing services.
Richcore has large scale fermentation capabilities and manufactures animal origin free (AOF) recombinant products.
These products help vaccine, insulin, stem-cell based regenerative medicine and other biopharma companies eliminate dependency on animal and human blood derived products and in turn produce safer medicines.

Disclaimer –
This document is meant for the recipient only for use as intended and not for circulation. This document should not be reproduced or copied or made available to others. The information contained herein is from the public domain or sources believed to be reliable. While reasonable care has been taken to ensure that information given is at the time believed to be fair and correct and opinions based thereupon are reasonable, due to the very nature of research it cannot be warranted or represented that it is accurate or complete and it should not be relied upon as such. Also above note is not a recommendation to Buy or SELL and is only a view based on facts and figures and we will be in no way responsible for any losses incurred by anyone who uses this information to either trade or invests securities mentioned herein.